HOME >> BIOLOGY >> NEWS
Animal studies show CA4P suppresses development and induces regression of ocular neovascularization

Watertown, Mass., July 31, 2003 OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) today announced the results of independent animal studies demonstrating the potential role of the Company's lead compound, Combretastatin A4 Prodrug (CA4P), in preventing and treating certain retinal degenerative diseases. Findings of the study are published in the current issue of the peer-reviewed journal Investigative Ophthalmology and Visual Science (IOVS).

The studies were conducted at The Johns Hopkins University School of Medicine by a team of researchers including Peter A. Campochiaro, M.D., a professor of ophthalmology at the school's renowned Wilmer Eye Institute. Dr. Campochiaro and Assistant Professor of Ophthalmology Quan Dong Nguyen, M.D. are leading the current Phase I/II clinical trial of CA4P in patients with wet age-related macular degeneration, known as wet AMD. Between 2 million and 3 million people in the United States have significant vision loss caused by wet AMD.

"The pre-clinical research produced by Dr. Campochiaro and his colleagues, as well as several other pre-clinical ophthalmic models using CA4P, provided the impetus for OXiGENE to move CA4P into human trials at Johns Hopkins," said Fred Driscoll, OXiGENE's president and CEO. "We are very pleased that Dr. Campochiaro considered the data from this study compelling enough to take CA4P into trials at one of the world's leading research institutions."

The study was designed to gauge CA4P's ability to suppress the development of choroidal neovascularization (CNV), a condition in which aberrant blood vessels beneath the retina leak blood and fluid into the retina. CNV is the primary cause of severe vision loss in patients with retinal degenerative diseases such as wet AMD. Researchers conducted experiments using transgenic mice with CNV caused by an over expression of vascular endothelial growth factor in the retina (rho/VEGF mice) and mice with laser-induced rupture of Bruch's memb
'"/>

Contact: Scott Solomon
ssolomon@investorrelations.com
617-542-5300
Sharon Merrill Associates, Inc.
31-Jul-2003


Page: 1 2

Related biology news :

1. Animal research suggests plant estrogens in soy do not increase breast cancer risk
2. Could vitamins raise levels of bad cholesterol? Animal study suggests they might
3. Animal studies show promise treating severe chronic pain
4. UF researcher: Animals think in their own way, but unlike humans
5. Animal study demonstrates carbon monoxide may help heart patients
6. Animals can be induced to cooperate if partners reciprocate and benefits accumulate
7. Animal study finds embryonic stem cells can repair heart muscle
8. Animal welfare can now be objectively measured
9. Animals regulate their numbers by own population density
10. UF researchers score gene therapy advance: Animal study shows high blood pressure prevented in future generations
11. Experimental Staph Vaccine Broadly Protective In Animal Studies

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/8/2019)... ... October 07, 2019 , ... The future of medicine in the 21st century ... people living longer, healthier lives. But it will be up to each individual to ... MD, PhD, Chief Strategy Officer and Co-Founder of the Institute for Systems Biology and ...
(Date:10/4/2019)... ... October 03, 2019 , ... Mount Sinai researchers have discovered how ... from one generation to the next. In a study published in Nature Structural & ... this enzyme, leading to cancers and other diseases. , “DNA polymerase delta serves as ...
(Date:10/3/2019)... , ... October 02, 2019 , ... Personalized Stem ... first patient in an FDA approved clinical trial for stem cell treatment of ... after formation of the company as a subsidiary of VetStem Biopharma. , PSC CEO, ...
Breaking Biology News(10 mins):
(Date:10/3/2019)... MURRIETA, Calif. (PRWEB) , ... October 02, 2019 , ... ... its business opportunity to investors and venture capital companies in Silicon Valley at a ... to 8:30 pm. The event will be held at the JJ Lake Business Center ...
(Date:10/3/2019)... ... 2019 , ... Yesterday, at the 2019 meeting of Outsourcing in Clinical Trials ... Sherley, M.D., Ph.D., discussed important design factors that currently limit the success of early ... suppliers of clinical trials, in his talk Dr. Sherley focused on the ...
(Date:9/24/2019)... Kong (PRWEB) , ... September 24, 2019 , ... Drug ... 2019 by the World Health Organization, with MRSA becoming one of the most serious ... there were 1,218 reported cases of community-associated MRSA (CA-MRSA), or a seven-fold of the ...
(Date:9/24/2019)... ... September 24, 2019 , ... The Grain Foods Foundation is ... Advisory Board. Dr. Holscher is an Assistant Professor of Nutrition in the Department ... the University of Illinois Urbana-Champaign, where she has affiliate appointments with the Institute ...
Breaking Biology Technology:
Cached News: